Cytochrome P-450 Enzyme Inhibitors

"Cytochrome P-450 Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES.

Descriptor ID	D065607
MeSH Number(s)	D27.505.389.500 D27.505.519.389.335
Concept/Terms	Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P 450 Enzyme Inhibitors P-450 Enzyme Inhibitors Enzyme Inhibitors, P-450 Inhibitors, P-450 Enzyme P 450 Enzyme Inhibitors P450 Enzyme Inhibitors Enzyme Inhibitors, P450 Inhibitors, P450 Enzyme Cytochrome P-450 Inhibitors Cytochrome P 450 Inhibitors Inhibitors, Cytochrome P-450 P-450 Inhibitors, Cytochrome Cytochrome P-450 Monooxygenase Inhibitors Cytochrome P-450 Monooxygenase Inhibitors Cytochrome P 450 Monooxygenase Inhibitors Cytochrome P-450-Dependent Monooxygenase Inhibitors Cytochrome P 450 Dependent Monooxygenase Inhibitors Cytochrome P-450 Oxygenase Inhibitors Cytochrome P-450 Oxygenase Inhibitors Cytochrome P 450 Oxygenase Inhibitors

Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 Enzyme Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Metabolic Side Effects of Drugs and Substances [D27.505.389]
Cytochrome P-450 Enzyme Inhibitors [D27.505.389.500]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Cytochrome P-450 Enzyme Inhibitors [D27.505.519.389.335]

Below are MeSH descriptors whose meaning is related to "Cytochrome P-450 Enzyme Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 Enzyme Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cytochrome P-450 Enzyme Inhibitors" by people in this website by year, and whether "Cytochrome P-450 Enzyme Inhibitors" was a major or minor topic of these publications.

Bar chart showing 8 publications over 7 distinct years, with a maximum of 2 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2000	1	0	1
2002	0	1	1
2009	1	0	1
2010	0	1	1
2014	1	0	1
2015	0	2	2

Below are the most recent publications written about "Cytochrome P-450 Enzyme Inhibitors" by people in Profiles.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015 Jun 01; 72(11):958-65.

View in: PubMed
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48.

View in: PubMed
Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015 Mar; 95:80-7.

View in: PubMed
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.

View in: PubMed
Dineen TA, Weiss MM, Williamson T, Acton P, Babu-Khan S, Bartberger MD, Brown J, Chen K, Cheng Y, Citron M, Croghan MD, Dunn RT, Esmay J, Graceffa RF, Harried SS, Hickman D, Hitchcock SA, Horne DB, Huang H, Imbeah-Ampiah R, Judd T, Kaller MR, Kreiman CR, La DS, Li V, Lopez P, Louie S, Monenschein H, Nguyen TT, Pennington LD, San Miguel T, Sickmier EA, Vargas HM, Wahl RC, Wen PH, Whittington DA, Wood S, Xue Q, Yang BH, Patel VF, Zhong W. Design and synthesis of potent, orally efficacious hydroxyethylamine derived ß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012 Nov 08; 55(21):9025-44.

View in: PubMed
Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011 Feb 02; 103(3):264-72.

View in: PubMed
Chun YJ, Oh YK, Kim BJ, Kim D, Kim SS, Choi HK, Kim MY. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicol Lett. 2009 Aug 25; 189(1):84-9.

View in: PubMed
Moorthy B, Miller KP, Jiang W, Ramos KS. The atherogen 3-methylcholanthrene induces multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1. Cardiovasc Res. 2002 Mar; 53(4):1002-9.

View in: PubMed
Moorthy B, Parker KM, Smith CV, Bend JR, Welty SE. Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole. J Pharmacol Exp Ther. 2000 Feb; 292(2):553-60.

View in: PubMed
Lillibridge JH, Amore BM, Slattery JT, Kalhorn TF, Nelson SD, Finnell RH, Bennett GD. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos. 1996 May; 24(5):509-14.

View in: PubMed

People

Explore

Similar Concepts

Top Journals